Board of Directors

Edwin Kania

Chairman of the Board, Vyriad, Inc.
Managing Partner, FarField Partners

Mr. Kania has taken an active role in the launch and development of numerous biotechnology and biopharmaceutical companies during his 35 years in the venture capital industry.  He is the managing partner of FarField Partners, a personal investment and advisory firm, and the co-founder and former Chairman of Flagship Ventures (now Flagship Pioneering), one of the largest venture capital firms launching and investing in U.S. biotechnology companies.  He continues as co-managing partner for several Flagship Funds and as an advisory partner to the firm.  Mr. Kania has served on the boards of dozens of public and private companies including Acceleron Pharma, Adolor Corp., Anesta Corp., ChemGenics Pharmaceuticals, Cytyc Corp., EXACT Sciences, IDEXX Laboratories, PerSeptive Biosystems, Somatogen, and Visterra. He is currently a director for Health Data Analytics Institute, Korrus/EcoSense, DataCore and TransMedics.  Mr. Kania received a master’s degree from Harvard Business School and bachelor’s degree in Physics from Dartmouth College.

Nathan Stacy

Senior Investment Officer
Mayo Clinic Treasury Services

Mr. Stacy manages a broad portfolio of private equity, venture capital and direct healthcare investments for Mayo Clinic Treasury Services.  He also serves on the advisory board for multiple private investment funds.  Through his current role that includes work with Mayo Clinic Ventures, the commercialization arm of the non-profit organization, Mr. Stacy has been involved in the spinout and financing of numerous life science technologies from Mayo Clinic.  Before joining Mayo Clinic, he held positions at Corixa Corporation, Lewin Group and the Congressional Budget Office.  He earned a bachelor’s degree from Duke University and a master’s degree from the University of Washington.

Stephen J. Russell, MD, PhD

President and Chief Executive Officer
Vyriad, Inc.

Dr. Russell is a world-renowned researcher in the field of gene and virus therapy.  He combines more than three decades of leadership as a clinician and researcher with extensive experience in all aspects of drug discovery and development.  A board-certified hematologist, Dr. Russell is a co-founder of Vyriad, the Richard O. Jacobson Professor of Molecular Medicine at Mayo Clinic and Vice President of the American Society of Gene and Cell Therapy.  Early in his career, Dr. Russell pioneered novel methods for engineering viral cancer immunotherapies.  He was a founder of Cambridge Genetics, a biotechnology company, and the European Society of Gene Therapy.  At the Mayo Clinic, Dr. Russell founded the Department of Molecular Medicine and built a comprehensive oncolytic virotherapy program.  He has authored more than 400 peer-reviewed research papers and is a frequent speaker at scientific and medical conferences.  Dr. Russell received his MD from the University of Edinburgh and a PhD from the University of London.

Glen Barber, PhD

Chairman & Professor
Department of Cell Biology, University of Miami

Dr. Barber is Chairman and Professor of the Department of Cell Biology and the Eugenia J. Dodson Chair in Cancer Research for the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.  He is an internationally recognized scientist in the field of innate immune defense and antiviral strategies.  Dr. Barber discovered the stimulator of interferon genes (STING) signaling pathway, its role in innate immunity and its potential as a target for anti-cancer therapies.  Dr. Barber has been developing novel vesicular stomatitis virus (VSV) therapeutics to eliminate cancer cells exhibiting defective innate immunity.  He is also Chief Executive Officer and President of STINGInn LLC, a company he founded based on his STING technology.  Dr. Barber is credited with more than 150 scientific publications, many in high-profile journals, including Nature, Science, and Cell.  He received his PhD in Molecular Virology at London University, England.

Ahryon Cho, PhD

General Manager
Mirae Asset Venture Investment

Dr. Cho is a general manager at Mirae Asset Venture Investment, the venture capital arm of Korea-based Mirae Asset Financial Group, a leading financial services group in Asia.  She has completed multiple equity investments in companies developing innovative therapeutics and diagnostics.  Previously, Dr. Cho was a research assistant professor at Yonsei University School of Medicine, Seoul, South Korea.  She received her Ph.D. in Molecular Biology and Neuroscience at Princeton University, NJ, USA, and completed her post-doctoral training in Pathology at Stanford University School of Medicine, CA, USA.

Andrew Khoo

Chief Executive Officer & Co-Founder
Tessa Therapeutics

Mr. Khoo leads Tessa Therapeutics, a Phase 3 biotechnology company specializing in virus-associated cancer immunotherapy.  Tessa’s core virus-specific T cell (VST) platform has shown compelling results in the treatment of solid tumors, and the company is building a portfolio of therapies for a wide range of cancer indications.  An active investor in healthcare and technology focused start-ups, Mr. Khoo is also a Director of Enleofen Bio, which is focused on the development and commercialization of antibodies to fibrotic diseases.  Prior to co-founding Tessa, Mr. Khoo worked in various roles at global banks including JP Morgan and Citigroup.  He began his career at the Singapore Economic Development Board and receiving a B.S. in Chemistry from Stanford University.